Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

ConferencepositiveBHV-1530cemiplimabPositive

AI Analysis

Summary

Biohaven announced Phase 1 dose-escalation data for BHV-1530, an FGFR3-directed ADC showing early tumor reductions, and established a clinical supply agreement with Regeneron to evaluate the drug in combination with cemiplimab. Data will be presented at ESMO Congress.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Phase 1 dose-escalation data show early tumor reductions in patients with FGFR3-altered tumors

Importance:6/10

Sentiment:

0.65

ADCFGFR3combination therapyclinical dataESMO Congresspartnership

Related Companies

$REGN

Read the original article

Published by PR Newswire Biotech on July 20, 2026 11:30 AM

Read Original